Eli Lilly Files 8-K: Director Changes and Officer Compensation
Ticker: LLY · Form: 8-K · Filed: Aug 16, 2024 · CIK: 59478
| Field | Detail |
|---|---|
| Company | Eli Lilly & Co (LLY) |
| Form Type | 8-K |
| Filed Date | Aug 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-changes
Related Tickers: LLY
TL;DR
Lilly's board is shuffling with new directors coming aboard and executive pay details emerging.
AI Summary
Eli Lilly and Company (LLY) filed an 8-K on August 16, 2024, reporting on the departure of director Michael J. Smith and the election of new directors, including Maria Teresa Rodriguez and David R. Johnson. The filing also details compensatory arrangements for certain officers and includes financial statements and exhibits related to the company's operations.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance matters and executive compensation, with no immediate financial distress or significant operational changes indicated.
Key Players & Entities
- Eli Lilly and Company (company) — Filer
- Michael J. Smith (person) — Departing Director
- Maria Teresa Rodriguez (person) — Newly Elected Director
- David R. Johnson (person) — Newly Elected Director
- 0000059478 (company) — Central Index Key for Eli Lilly
FAQ
Who has departed from Eli Lilly's board of directors?
Michael J. Smith has departed from Eli Lilly's board of directors.
Who are the newly elected directors at Eli Lilly?
Maria Teresa Rodriguez and David R. Johnson have been elected as new directors.
What other items are covered in this 8-K filing besides director changes?
The filing also covers compensatory arrangements of certain officers and includes financial statements and exhibits.
When was this 8-K form filed?
This 8-K form was filed on August 16, 2024.
What is the primary business of Eli Lilly & Co. according to the filing?
Eli Lilly & Co. is primarily involved in Pharmaceutical Preparations, with SIC code 2834.
Filing Stats: 599 words · 2 min read · ~2 pages · Grade level 8.9 · Accepted 2024-08-16 16:16:48
Filing Documents
- lly-20240813.htm (8-K) — 49KB
- praugust2024.htm (EX-99.1) — 9KB
- image_1.jpg (GRAPHIC) — 86KB
- picture1.jpg (GRAPHIC) — 19KB
- 0000059478-24-000196.txt ( ) — 422KB
- lly-20240813.xsd (EX-101.SCH) — 5KB
- lly-20240813_def.xml (EX-101.DEF) — 19KB
- lly-20240813_lab.xml (EX-101.LAB) — 37KB
- lly-20240813_pre.xml (EX-101.PRE) — 20KB
- lly-20240813_htm.xml (XML) — 10KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Eli Lilly and Company, dated August 16, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ELI LILLY AND COMPANY (Registrant) By: /s/ Anat Hakim Name: Anat Hakim Title: Executive Vice President, General Counsel and Secretary Date: August 16, 2024